Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Troxacitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.60 |
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troxacitabine SCHEMBL1026150 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL18548 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1026148 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1653267 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL6424800 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1844439 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL22285889 | 0.99 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL17542009 | 0.95 | LMNA (0.56) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL7560355 | 0.89 | POLG (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL31347648 | 0.88 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111956646-B | Combination therapy of sorafenib or regorafenib with phosphoramidate prodrugs of troxacitabine | 麦迪维尔股份公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |